[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iparomlimab-and-tuvonralimab-injection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iparomlimab-and-tuvonralimab-injection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100632575","phase-2-a-prospective-single-arm-exploratory-study-of-the-safety-and-efficacy-of-neoadjuvant-treatment-with-ql1706-an-anti-pd-1anti-ctla-4-bispecific-antibody-in-resectable-stage-ib-and-iia-hepatocellular-carcinoma-with-high-recurrence-risk-100632575",false,"NCT07515469","A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1\u002FAnti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk","A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With Iparomlimab and Tuvonralimab Injection, an Anti-PD-1\u002FAnti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk","Inclusion Criteria:\n\n* Patients voluntarily participate in this study and sign the informed consent form.\n* Aged 18 to 75 years, male or female.\n* ECOG Performance Status (PS) score of 0 to 1.\n* Child-Pugh liver function classification: Grade A.\n* Histopathologically confirmed primary hepatocellular carcinoma (HCC), and the lesions meet the surgical resection indications specified in the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).\n* Preoperatively, evaluated by the investigator, with high recurrence risk factors, meeting at least one of the following: Stage IB: Single tumor with maximum diameter \\> 5 cm; 2-3 tumors with maximum tumor diameter ≤ 3 cm；Stage IIA: 2-3 tumors with maximum tumor diameter \\> 3 cm.\n* According to the RECIST 1.1 criteria, the patient has at least one measurable lesion (measurable lesion with a long diameter ≥ 10 mm on CT\u002FMRI scan or lymph node lesion with a short diameter ≥ 15 mm on CT\u002FMRI scan, and the measurable lesion has not received local treatment such as radiotherapy or cryotherapy).\n* Expected survival time ≥ 6 months\n* possess normal and sound organ function\n* Females of childbearing age must agree to use contraceptive measures (such as intrauterine device, contraceptives or condoms) during the medication period and within 6 months after the end of medication; serum or urine pregnancy test is negative within 7 days before study enrollment, and must be a non-lactating patient; males must agree to use contraceptive measures during the study period and within 6 months after the end of the study.\n* The subject has good compliance and is willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n* Previous radiotherapy, chemotherapy, concurrent chemoradiotherapy or other targeted therapy.\n* Known hilar cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar carcinoma; other active malignant tumors except HCC within 5 years or concurrently.\n* Hypertension that cannot be well controlled with antihypertensive drugs (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); previous hypertensive crisis or hypertensive encephalopathy.\n* The subject has a history of other malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) or concurrent malignant tumors.\n* Previous treatment with Iparomlimab and Tuvonralimab or other PD-1\u002FPD-L1\u002FCTLA-4 inhibitors; known previous allergy of the subject to macromolecular protein preparations or any component of Iparomlimab and Tuvonralimab.\n* The subject has any active autoimmune disease or a history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism); subjects with vitiligo or asthma that was completely relieved in childhood and does not require any intervention in adulthood can be included; subjects with asthma requiring medical intervention with bronchodilators cannot be included.\n* The subject is using immunosuppressants, or systemic or absorbable local hormone therapy for immunosuppressive purposes (dose \\> 10 mg\u002Fday prednisone or other hormones with equivalent efficacy), and continues to use them within 2 weeks before enrollment.\n* Clinically symptomatic ascites or pleural effusion requiring therapeutic paracentesis or drainage.\n* Uncontrolled clinical symptoms or diseases of the heart, such as: Heart failure of NYHA Class II or above；Unstable angina pectoris；Myocardial infarction within 1 year；Patients with clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.\n* The patient currently (within 3 months) has esophageal varices, active gastroduodenal ulcer, ulcerative colitis, portal hypertension and other digestive tract diseases, or active bleeding from unresected tumors, or other conditions judged by the investigator that may cause gastrointestinal bleeding or perforation.\n* Previous or current severe bleeding (bleeding \\> 30 ml within 3 months), hemoptysis (\\> 5 ml of fresh blood within 4 weeks) or thromboembolic events (including stroke events and\u002For transient ischemic attack) within 12 months.\n* The subject has an active infection or unexplained fever \\> 38.5 ℃ during screening or before the first dose (fever caused by tumor can be included as judged by the investigator).\n* Patients with objective evidence of previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc.\n* The subject has congenital or acquired immunodeficiency, such as HIV infection, or active hepatitis (transaminase does not meet the inclusion criteria; for hepatitis B: HBV DNA ≥ 10⁴\u002Fml; for hepatitis C: HCV RNA ≥ 10³\u002Fml); chronic hepatitis B virus carriers with HBV DNA \\\u003C 2000 IU\u002Fml (\\\u003C 10⁴ copies\u002Fml) can be enrolled only if they receive antiviral treatment during the trial.\n* Live vaccine接种 within 4 weeks before study medication or likely to be vaccinated during the study period.\n* The subject has a known history of psychotropic drug abuse, alcoholism or drug addiction.\n* The investigator deems that the subject should be excluded from this study, for example, as judged by the investigator, the subject has other factors that may lead to the forced termination of the study in the middle, such as other serious diseases (including mental diseases) requiring combined treatment, severe laboratory test abnormalities, or family or social factors that may affect the safety of the subject or the collection of data and samples.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study aims to investigate the efficacy and safety of neoadjuvant therapy with Iparomlimab and Tuvonralimab Injection (anti-PD-1 and anti-CTLA-4 antibody combination) in patients with resectable hepatocellular carcinoma at high risk of recurrence (Stage IB, Stage IIA).",[27,28,29],"HCC - Hepatocellular Carcinoma","Iparomlimab and Tuvonralimab Injection","Neoadjuvant Immunotherapy","NOT_YET_RECRUITING","2026-03-31",{"date":33,"type":34},"2026-04-07","ACTUAL",{"date":36,"type":21},"2026-05-30",{"date":38,"type":21},"2030-10-30",{"name":40,"class":41},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100619374","early-phase-1-efficacy-and-safety-study-of-dc-cik-cell-therapy-combined-with-epaloliposide-vortexil-and-regorafenib-as-third-line-treatment-for-advanced-colorectal-cancer-100619374","NCT07343791","Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","Inclusion Criteria:\n\n-1. Sign written informed consent before implementing any experimental procedures; 2. Male or female ≥ 18 years old, ≤ 75 years old; 3. ECOG PS score is 0-1 points; 4. Patients with metastatic colorectal cancer confirmed by histology or cytology; 5. Expected survival time\\>3 months;\n\nExclusion Criteria:\n\n-1. It is known that there is active CNS metastasis and\u002For cancerous meningitis; 2. Chest fluid, ascites, and pericardial effusion that require drainage due to clinical symptoms; 3. Any life-threatening bleeding events that have occurred within the past 3 months, including the need for blood transfusion therapy, surgery or local treatment, and continuous medication therapy; 4. Uncontrollable hypertension, with systolic blood pressure\\>150mmHg or diastolic blood pressure\\>90 mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy; 5. Human immunodeficiency virus (HIV) infected individuals (HIV 1\u002F2 antibody positive), known syphilis infected individuals;",{"count":49,"type":21},14,[51],"EARLY_PHASE1","Research background and purpose:\n\nPatients with advanced colorectal cancer face the dilemma of limited treatment options and poor efficacy in the third line treatment stage. Although regorafenib and immune checkpoint inhibitors bring hope to some patients, the efficacy still faces bottlenecks for the vast majority of microsatellite stable patients who are insensitive to immune monotherapy. This study is based on the multi mechanism synergistic theory of \"immune activation+vascular inhibition+targeted killing\". It innovatively combines autologous DC-CIK cell immunotherapy, domestic PD-1\u002FCTLA-4 bispecific antibody (aparolitovorelli monoclonal antibody), and multi-target tyrosine kinase inhibitor (regorafenib) to evaluate the efficacy and safety of this triple therapy as a third line treatment for advanced colorectal cancer, and explore its immunological mechanism.\n\nResearch content and methods:\n\nThis study is a single arm, open label clinical trial. Plan to enroll advanced colorectal cancer patients who have previously failed second-line standard treatment. All participants will receive the following combination therapy regimen:\n\n1. Epaglitovirizumab: 5.0 mg\u002Fkg, intravenous injection, once every 21 days.\n2. Regorafenib: 120mg, once daily, orally, 1-21 days, repeated every 28 days.\n3. DC-CIK cell therapy: Collect, culture, and transfuse cells during specific cycles.\n\nThe study will strictly follow the protocol for efficacy evaluation (based on RECIST 1.1 standards) and safety monitoring, and a strict quality control and risk management system will be established.\n\nMain evaluation indicators and expected outcomes:\n\n* Primary endpoint: Objective response rate and safety.\n* Secondary endpoints: progression free survival, overall survival, duration of remission, and treatment-related immunological responses.\n* Expected outcome: This study is expected to provide a promising new comprehensive treatment strategy for chemotherapy resistant advanced colorectal cancer, especially MSS type patients, and break through existing efficacy bottlenecks. The research findings will provide high-level evidence-based medicine for the clinical application of this combined approach and lay the foundation for understanding its synergistic mechanism.",[54,55,56,57,28],"DC-CIK Treatment","Regorafenib","Colorectal Cancer","Immune Combination Therapy",[59,55,60,61,28],"DC-CIK treatment","colorectal cancer","Immune combination therapy","RECRUITING","2026-01-14",{"date":65,"type":34},"2026-01-15",{"date":67,"type":34},"2025-11-19",{"date":69,"type":21},"2027-11-30",{"name":71,"class":41},"JIANG LONGWEI",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100618143","phase-2-ql1706-in-combination-with-bevacizumab-and-ralox-haic-for-hepatocellular-carcinoma-with-vp34-pvtt-100618143","NCT07327788","QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3\u002F4 PVTT","Iparomlimab and Tuvonralimab (QL1706) With Bevacizumab and RALOX Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma (HCC) With Vp3\u002F4 Portain Vein Thrombosis : A Prospective, Multicenter, Phase II Study","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. Aged ≥ 18 years, male and female subjects are both eligible;\n3. Clinically or pathologically confirmed hepatocellular carcinoma (HCC), with no prior systemic anti-tumor therapy for HCC (including but not limited to molecular targeted therapy, systemic chemotherapy, immunotherapy such as anti-PD-1\u002FPD-L1\u002FCTLA-4 monoclonal antibodies, etc.);\n4. Complicated with Type VP3 or VP4 portal vein tumor thrombosis (PVTT);\n5. Confirmed to have at least one measurable target lesion by imaging examination during the screening period in accordance with RECIST v1.1 criteria. The measurable lesions should not have received local treatment such as radiotherapy (lesions within the area of previous local treatment can also be selected as target lesions if disease progression is confirmed);\n6. Child-Pugh score ≤ 7 points (Child-Pugh class A-B);\n7. The maximum diameter of liver tumor ≥ 7 cm;\n8. ECOG performance status 0 to 1;\n9. Expected survival time ≥ 12 weeks;\n10. Function of vital organs meeting the following requirements:\n\nAbsolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; Platelet count ≥ 50×10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Serum albumin ≥ 29 g\u002FL; Bilirubin ≤ 2 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN, alkaline phosphatase (AKP) ≤ 5 × ULN; Serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl) ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault formula; 11.Eligible patients with reproductive potential (males and females) must agree to use a reliable contraceptive method (hormonal, barrier method or abstinence) with their partners during the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first study medication administration.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocellular carcinoma, mixed hepatocellular carcinoma, etc.;\n2. Active autoimmune disease, or a history of autoimmune disease with potential for recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism \\[patients whose condition is controllable only with hormone replacement therapy are not excluded\\]); Note: Patients with dermatological diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, alopecia), type 1 diabetes with good glycemic control under insulin therapy, or asthma that achieved complete remission in childhood and requires no intervention in adulthood are eligible for enrollment; patients with asthma requiring medical intervention with bronchodilators are ineligible.\n3. Administration of immunosuppressants or systemic hormonal therapy for immunosuppressive purposes within 2 weeks prior to the first study medication (dose \\> 10 mg\u002Fday prednisone or an equivalent dose of other hormones);\n4. Current interstitial pneumonia or interstitial lung disease, a history of interstitial pneumonia or interstitial lung disease requiring hormonal therapy, or other pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia that may interfere with the judgment and management of immune-related pulmonary toxicity; patients with evidence of active pneumonia on screening CT or severe impairment of pulmonary function are excluded. Radiation pneumonitis within the radiation field is permitted;\n5. Confirmed active pulmonary tuberculosis. For subjects with suspected active pulmonary tuberculosis, a definitive diagnosis shall be made based on chest imaging, sputum examination, and clinical symptoms and signs;\n6. Known hypersensitivity to the active ingredients or excipients of the study drugs, or a history of severe hypersensitivity to any other monoclonal antibody or anti-angiogenic targeted drugs;\n7. Known history of central nervous system (CNS) metastasis or hepatic encephalopathy;\n8. A history of allogeneic stem cell transplantation or solid organ transplantation;\n9. Moderate to severe ascites with clinical symptoms requiring therapeutic paracentesis or drainage (except for patients with only a small amount of ascites shown by imaging without clinical symptoms), or uncontrolled moderate to large pleural effusion or pericardial effusion;\n10. Severe cardiovascular and cerebrovascular diseases, including but not limited to:\n\n(1) Severe cardiac rhythm or conduction abnormalities (e.g., ventricular or supraventricular arrhythmias requiring clinical intervention, grade Ⅱ-Ⅲ atrioventricular block), QTcF interval ≥ 450 ms (males) or QTcF interval ≥ 470 ms (females) (if the QTcF interval is abnormal at screening, two additional tests shall be performed at an interval of at least 5 minutes, and the average value shall be taken); unstable angina pectoris, etc.; (2) Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, transient ischemic attack (TIA) or other grade 3 and above cardiovascular and cerebrovascular events within 6 months prior to the first study medication; (3) New York Heart Association (NYHA) cardiac function classification ≥ grade II or left ventricular ejection fraction (LVEF) \\\u003C 50%; (4) Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg after treatment with two or more antihypertensive drugs); 11.Coagulation dysfunction (INR \\> 2.0, prothrombin time (PT) prolonged by more than 6 seconds), with obvious bleeding tendency or other evidence of major coagulation disorders: clinically significant hemoptysis or tumor bleeding of any cause within 2 weeks prior to the first study medication; a history of thrombosis or embolism within 6 months prior to the first study medication; therapeutic anticoagulant therapy (except low-molecular-weight heparin) within 2 weeks prior to the first study medication; or antiplatelet therapy (e.g., aspirin \\> 325 mg\u002Fday, clopidogrel \\> 75 mg\u002Fday, dipyridamole, ticlopidine, cilostazol) within 10 days prior to the first study medication, or patients requiring long-term antiplatelet therapy; patients with metastatic lesions invading large blood vessels, respiratory tract or middle mediastinum with a significant risk of bleeding; 12.A history of esophageal or gastric variceal bleeding caused by portal hypertension within 6 months prior to the first study medication; confirmed severe varices by endoscopy within 3 months prior to the first study medication; or evidence of portal hypertension (including splenomegaly detected by imaging) with a high risk of bleeding assessed by the investigator (including moderate to severe esophagogastric varices with bleeding risk, active local peptic ulcer, and persistent positive fecal occult blood, which require gastroscopy to exclude patients with \"red signs\". Patients with a history of \"red signs\" on gastroscopy are excluded); 13.Any life-threatening bleeding event within 3 months prior to the first study medication, including those requiring blood transfusion, surgery or local treatment, and continuous drug therapy; 14.A history of abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months prior to the first study medication; 15.A history of intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months prior to the first study medication, including incomplete obstruction related to the primary disease or requiring routine parenteral hydration, parenteral nutrition or tube feeding; 16.Severe unhealed wounds, active ulcers or untreated fractures; 17.Urinalysis showing urine protein ≥ ++ with a confirmed 24-hour urine protein excretion \\> 1.0 g; 18.Severe infection within 4 weeks prior to the first study medication (including but not limited to hospitalization due to infection, bacteremia or severe pneumonia complications); active infection requiring oral or intravenous therapeutic antibiotics within 2 weeks prior to the first study medication (patients receiving prophylactic antibiotics, e.g., for prevention of urinary tract infection or acute exacerbation of chronic obstructive pulmonary disease, are eligible); unexplained fever ≥ 38.5℃ within 7 days prior to medication administration, or baseline white blood cell count \\> 15×10⁹\u002FL; 19.Congenital or acquired immune deficiency (e.g., HIV-infected patients), or confirmed active syphilis infection; 20.A history of other malignant tumors except HCC within 5 years prior to the first study medication or concurrent malignant tumors. Patients with the following cured localized tumors are eligible for enrollment: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc.; 21.Hepatic surgery, local treatment for HCC or investigational drug therapy within 4 weeks prior to the first study medication; administration of traditional Chinese medicine preparations with anti-HCC effects within 2 weeks prior to the first study medication; or toxic reactions caused by previous treatment (except alopecia) that have not recovered to ≤ grade 1 (per NCI-CTCAE v5.0); 22.Administration of drugs with immunomodulatory effects (including but not limited to interferon, interleukin) within 2 weeks prior to the first study medication; 23.Participation in other clinical studies and administration of other investigational drugs within 4 weeks prior to the first study medication; 24.Administration of live attenuated vaccines within 4 weeks prior to the first study medication, or anticipated need for such vaccination during the study treatment or within 90 days after the last study medication; 25.Major surgery (except for diagnostic purposes) within 4 weeks prior to the first study medication, or anticipated major surgery during the study period (major surgery is defined as surgery performed under general anesthesia that requires a recovery period of at least 3 weeks before initiation of study drug treatment); tissue biopsy or other minor surgical procedures within 7 days prior to the first study medication, except for venous catheterization for intravenous infusion; 26.Pregnant or lactating women, or women of childbearing potential who refuse to take contraceptive measures; 27.Other factors judged by the investigator that may affect the study results or lead to forced early termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring combined treatment, severe abnormal laboratory tests, or family\u002Fsocial factors that may affect patient safety.",{"count":81,"type":21},38,[24],"The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver cancer patients with VP3\u002F4 portal vein tumor thrombus. It will also explore molecular biomarkers that predict the efficacy of this combined therapy.\n\nThe main questions it aims to answer are:\n\nWhat is the progression-free survival (PFS) of patients treated with this regimen? What are the objective response rate (ORR), disease control rate (DCR), and overall survival (OS) of these patients? What is the safety and tolerability profile of this combined treatment? Which molecular biomarkers can predict the efficacy of this therapy? Eligible subjects (who have signed informed consent) will receive RALOX hepatic artery infusion chemotherapy plus QL1706 (7.5mg, intravenous infusion every 3 weeks) and bevacizumab (15mg\u002Fkg, intravenous infusion every 3 weeks), with 3 weeks as one treatment cycle. Treatment will continue until a protocol-specified discontinuation event occurs. After treatment, subjects will undergo post-treatment safety follow-up and survival follow-up; those who discontinue treatment for reasons other than disease progression or death will also have tumor progression follow-up.",[85,86,87,88,28,89],"Hepatecellular Carcinoma","RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin","Bevacizumab","Type VP3\u002F4 Portal Vein Tumor Thrombosis","QL1706","2026-01-11",{"date":92,"type":34},"2026-01-13",{"date":94,"type":21},"2025-12-25",{"date":96,"type":21},"2028-12-30",{"name":98,"class":41},"Nanfang Hospital, Southern Medical University"]